Antifosfolipidantistoffer og antifosfolipidsyndrom

Rasmus Søgaard Hansen; Julie Brogaard Larsen; Pernille Just Vinholt; Anne Voss; Anders Abildgaard

doi:10.61409/V11230715

Antifosfolipidantistoffer og antifosfolipidsyndrom

Rasmus Søgaard Hansen, Julie Brogaard Larsen, Pernille Just Vinholt, Anne Voss, Anders Abildgaard

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Review › Forskning › peer review

Abstract

Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti-β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.

Bidragets oversatte titel	Antiphospholipid antibodies and antiphospholipid syndrome
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Læger
Vol/bind	186
Nummer	21
ISSN	0041-5782
DOI	https://doi.org/10.61409/V11230715
Status	Udgivet - 20 maj 2024

Adgang til dokumentet

10.61409/V11230715Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{090f7a097f5c49069790c76e0b6d707c,

title = "Antifosfolipidantistoffer og antifosfolipidsyndrom",

abstract = "Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti-β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.",

author = "Hansen, {Rasmus S{\o}gaard} and Larsen, {Julie Brogaard} and Vinholt, {Pernille Just} and Anne Voss and Anders Abildgaard",

note = "Publisher Copyright: Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = may,

day = "20",

doi = "10.61409/V11230715",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Den Almindelige Danske L{\ae}geforening",

number = "21",

}

TY - JOUR

T1 - Antifosfolipidantistoffer og antifosfolipidsyndrom

AU - Hansen, Rasmus Søgaard

AU - Larsen, Julie Brogaard

AU - Vinholt, Pernille Just

AU - Voss, Anne

AU - Abildgaard, Anders

N1 - Publisher Copyright: Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/5/20

Y1 - 2024/5/20

N2 - Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti-β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.

AB - Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti-β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.

UR - http://www.scopus.com/inward/record.url?scp=85195438751&partnerID=8YFLogxK

U2 - 10.61409/V11230715

DO - 10.61409/V11230715

M3 - Review

C2 - 38847311

AN - SCOPUS:85195438751

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 21

ER -

Antifosfolipidantistoffer og antifosfolipidsyndrom

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater